Molecular typing and marker screening of adamantinomatous craniopharyngioma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200059854

Enrollment

Unknown

Registered

2022-05-13

Start date

2022-12-01

Completion date

Unknown

Last updated

2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniopharyngioma

Interventions

Immune group:None

Eligibility

Sex/Gender

All

Age

No minimum to 80 Years

Inclusion criteria

Inclusion criteria: 1. Cases admitted to our hospital for surgery from January 2017 to the study period; 2. Approved by the ethics committee and signed informed consent by the patients; 3. Tumor tissue specimens of primary and recurrent ACP patients, regardless of gender and age.

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone radiation therapy and/or intracystic chemotherapy and/or systemic chemotherapy.

Design outcomes

Primary

Measure	Time frame
Height;Weight;Hormone levels;Head imaging;	—

Secondary

Measure	Time frame
Urine output;Biochemical Indicators;	—

Countries

China

Contacts

Public ContactZhixiong Lin

Sanbo Brain Hospital of Capital Medical University

linzx@ccmu.edu.cn+86 13905918963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026